Surveillance after treatment for head and neck cancer
Koivunen, Petri
Koivunen, Petri
Lippincott Williams & Wilkins
Koivunen, P. (2026). Surveillance after treatment for head and neck cancer. Current Opinion in Otolaryngology & Head & Neck Surgery, 34(2), 83–87. https://doi.org/10.1097/MOO.0000000000001102
https://creativecommons.org/licenses/by/4.0/
© 2026 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
https://creativecommons.org/licenses/by/4.0/
© 2026 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
https://creativecommons.org/licenses/by/4.0/
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:oulu-202603092062
https://urn.fi/URN:NBN:fi:oulu-202603092062
Tiivistelmä
Abstract
Purpose of review:
Systematic follow-up protocols, often including regular imaging, are an essential component of posttreatment care for head and neck cancer, aimed at the early detection of disease relapse and mitigating treatment-related morbidity. However, there is no consensus on the optimal length of follow-up and the value of imaging in surveillance.
Recent findings:
Most head and neck cancer recurrences occur within 1–2 years after treatment. After 2 years, the recurrence rate decreases significantly, and after 3 years, recurrences are infrequent. Most of the recent studies suggest that prolonged scheduled follow-up programs are not necessary, as asymptomatic salvageable late recurrences are rare. Imaging surveillance for the early detection of otherwise undetected recurrences is supported by many studies, although its impact on survival remains unclear.
Summary:
Recent literature emphasizes intensive follow-up programs during 1–2 years, as well as patient education for self-observation of alarming symptoms. Prolonged surveillance programs after 2–3 years may not be effective in detecting asymptomatic recurrences. While personalized surveillance based on risk factors is suggested, a lack of strict evidence hampers stratification. Imaging may be of value in detecting early asymptomatic recurrences at least up to 2 years, but disagreement exists regarding its utility in improving survival.
Purpose of review:
Systematic follow-up protocols, often including regular imaging, are an essential component of posttreatment care for head and neck cancer, aimed at the early detection of disease relapse and mitigating treatment-related morbidity. However, there is no consensus on the optimal length of follow-up and the value of imaging in surveillance.
Recent findings:
Most head and neck cancer recurrences occur within 1–2 years after treatment. After 2 years, the recurrence rate decreases significantly, and after 3 years, recurrences are infrequent. Most of the recent studies suggest that prolonged scheduled follow-up programs are not necessary, as asymptomatic salvageable late recurrences are rare. Imaging surveillance for the early detection of otherwise undetected recurrences is supported by many studies, although its impact on survival remains unclear.
Summary:
Recent literature emphasizes intensive follow-up programs during 1–2 years, as well as patient education for self-observation of alarming symptoms. Prolonged surveillance programs after 2–3 years may not be effective in detecting asymptomatic recurrences. While personalized surveillance based on risk factors is suggested, a lack of strict evidence hampers stratification. Imaging may be of value in detecting early asymptomatic recurrences at least up to 2 years, but disagreement exists regarding its utility in improving survival.
Kokoelmat
- Avoin saatavuus [43406]

